Ignite Creation Date:
2024-05-05 @ 10:10 PM
Last Modification Date:
2024-10-26 @ 10:15 AM
Study NCT ID:
NCT01049854
Status:
COMPLETED
Last Update Posted:
2018-08-21
First Post:
2008-05-05
Brief Title:
CD34Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Sponsor:
New York Medical College
Organization:
New York Medical College
Study Overview
Official Title:
CD34Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CD34 stem cell selection in children adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious Grade IIIIV acute and chronic graft versus host disease GVHD
Detailed Description:
The selection of CD34 cells is associated with the simultaneous depletion of T cells that are responsible for severe acute and chronic graft versus host disease GVHD Successful engraftment is reported in adult patients with malignant and non-malignant disease who received CD34 selected stem cells from HLA-matched or mismatched mobilized peripheral blood PBSC or bone marrow
Study Design
Selected patients defined in the eligibility criteria will enrolled on this study Patients will receive one of either full intensity or reduced intensity regimen based on the patients disease status organ function and performance and determined by the PI and will have peripheral blood undergo CD34 selection
Study Design
Selected patients defined in the eligibility criteria will enrolled on this study Patients will receive one of either full intensity or reduced intensity regimen based on the patients disease status organ function and performance and determined by the PI and will have peripheral blood undergo CD34 selection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NYMC 525 | OTHER | NYMC | None |